Hyperliquid Strategies Inc - Common Stock (PURR)
12.83
+1.27 (10.99%)
NASDAQ· Last Trade: Aug 27th, 4:51 PM EDT
Detailed Quote
| Previous Close | 11.56 |
|---|---|
| Open | 12.18 |
| Bid | 13.13 |
| Ask | 13.20 |
| Day's Range | 11.96 - 14.14 |
| 52 Week Range | 3.010 - 12.10 |
| Volume | 42,134,512 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 14,835,363 |
Chart
News & Press Releases
Hyperliquid Strategies Inc (NASDAQ:PURR) shares are surging to new all-time highs Thursday after the company reported fiscal-year results.
Via Benzinga · August 27, 2026
Hyperliquid Strategies (NASDAQ:PURR) reported fiscal 2026 results highlighted by gains on its HYPE token treasury, growing staking revenue and a balance sheet with more than $2 billion in assets and no debt as of June 30.
Chief Executive Officer David Schamis said the company held 29.4 million HYPE
Via MarketBeat · August 27, 2026
This move implies that a new category of investors is now taking interest in Hyperliquid.
Via The Motley Fool · August 24, 2026
There's a lot more to their purchasing than a desire to own Hyperliquid itself.
Via The Motley Fool · August 22, 2026
Hyperliquid Strategies Inc (NASDAQ:PURR) shares surged this week after President Donald Trump signaled support for bringing the Hyperliquid exchange into the U.S. under a compliant regulatory structure.
Via Benzinga · August 20, 2026
When the macroeconomic backdrop is as unstable as it is right now, it pays to be careful what you buy.
Via The Motley Fool · July 15, 2026
MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Long PURR ETF (Nasdaq: PUR), the first ETF designed to provide 2X daily leveraged exposure to Hyperliquid Strategies Inc. (Nasdaq: PURR). Now trading, PUR gives active traders amplified, single-ticker exposure to PURR, a digital asset treasury and investment company focused on the Hyperliquid Layer-1 blockchain ecosystem and its native token, HYPE.
By Defiance ETFs · Via GlobeNewswire · July 8, 2026

These companies work best when the prices of their underlying assets are rising rather than falling.
Via The Motley Fool · June 29, 2026
This coin gains when investors use its platform to speculate on the prices of hot stocks.
Via The Motley Fool · June 22, 2026
The crypto market's pullback is revealing that many valuations were based solely on hot air.
Via The Motley Fool · June 13, 2026
Arthur Hayes bet $100,000 that Hyperliquid, as measured by Hyperliquid Strategies Inc (NASDAQ:PURR) outperforms every other top 10 crypto
Via Benzinga · June 2, 2026
A few different players are taking an interest in the network.
Via The Motley Fool · June 1, 2026
The investment bank has clearly had a change of heart regarding which cryptocurrencies it thinks are worth owning.
Via The Motley Fool · May 28, 2026
Coinbase Global and Hyperliquid Strategies are ideally positioned to capture institutional capital as tokenized securities modernize global equity markets.
Via MarketBeat · May 21, 2026
Hyperliquid Strategies (NASDAQ:PURR) reported a profitable fiscal third quarter, with results driven primarily by appreciation in the HYPE token and continued staking revenue, executives said on the company’s third-quarter 2026 earnings call.
CEO David Schamis said the company remains “by far the l
Via MarketBeat · May 8, 2026
This is an important decision if you want exposure to the growth of crypto derivatives.
Via The Motley Fool · May 2, 2026
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · April 10, 2026
Hyperliquid’s (NASDAQ:PURR) oil perpetual futures contract hit $1.7 billion in daily trading volume as non-crypto traders sought 24/7 oil exposure during the Iran war
Via Benzinga · March 19, 2026
BitMEX co-founder Arthur Hayes says he has re-entered his Hyperliquid (NASDAQ:PURR) trade, predicting the asset could surge more than fourfold if the p
Via Benzinga · March 16, 2026
As pharmaceutical companies race to develop treatments for metabolic dysfunction–associated steatohepatitis (MASH) and related steatotic liver disease (SLD), one critical piece of the healthcare puzzle is drawing increasing attention: how to diagnose and monitor millions of patients at scale . While most investor focus remains on drug developers, ENDRA Life Sciences (NASDAQ: NDRA) is positioning itself on the infrastructure side of the emerging MASH ecosystem with its innovative TAEUS® (Thermo-Acoustic Enhanced UltraSound) liver imaging technology.
Via AB Newswire · March 9, 2026
